See more : ACI Infocom Limited (ACIIN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of BioPlus Acquisition Corp. (BIOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPlus Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Fiem Industries Limited (FIEMIND.BO) Income Statement Analysis – Financial Results
- South Dakota Soybean Processors, LLC (SDSYA) Income Statement Analysis – Financial Results
- Shineco, Inc. (TYHT) Income Statement Analysis – Financial Results
- Aspial Corporation Limited (A30.SI) Income Statement Analysis – Financial Results
- Global Industrial Company (GIC) Income Statement Analysis – Financial Results
BioPlus Acquisition Corp. (BIOS)
About BioPlus Acquisition Corp.
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
| Metric | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 708.90M | 817.20M | 935.60M | 982.20M | 984.10M | 842.20M | 662.60M | 0.00 | 1.64B | 1.33B | 1.40B | 1.20B | 1.15B | 1.07B | 630.50M | 588.80M | 576.60M | 456.60M | 369.80M | 377.40M | 451.10M | 242.30M | 283.20M | 213.90M | 109.30M | 100.00K |
| Cost of Revenue | 1.17M | 0.00 | 465.90M | 547.90M | 670.00M | 721.30M | 723.00M | 570.40M | 437.70M | 0.00 | 1.38B | 1.17B | 1.26B | 1.06B | 1.03B | 957.00M | 562.40M | 520.20M | 506.00M | 403.20M | 334.60M | 347.10M | 421.40M | 239.00M | 278.10M | 213.40M | 106.70M | 0.00 |
| Gross Profit | -1.17M | 0.00 | 243.00M | 269.30M | 265.60M | 260.90M | 261.10M | 271.80M | 224.90M | 0.00 | 260.40M | 157.80M | 142.20M | 137.00M | 119.60M | 116.20M | 68.10M | 68.60M | 70.60M | 53.40M | 35.20M | 30.30M | 29.70M | 3.30M | 5.10M | 500.00K | 2.60M | 100.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 34.28% | 32.95% | 28.39% | 26.56% | 26.53% | 32.27% | 33.94% | 0.00% | 15.89% | 11.87% | 10.14% | 11.44% | 10.38% | 10.83% | 10.80% | 11.65% | 12.24% | 11.70% | 9.52% | 8.03% | 6.58% | 1.36% | 1.80% | 0.23% | 2.38% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.17K | 162.43 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Other Expenses | 1.17M | 0.00 | 189.60M | 220.80M | 197.70M | 465.00M | 35.10M | 40.70M | 13.10M | 4.80M | 27.90M | 1.80M | 96.60M | 2.90M | 6.60M | 36.10M | 3.00M | 1.90M | 500.00K | -200.00K | 1.50M | 7.10M | 4.00M | 0.00 | 26.60M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.17M | 162.43 | 236.90M | 284.10M | 263.70M | 548.60M | 354.50M | 294.70M | 211.60M | 4.80M | 254.20M | 142.40M | 225.70M | 128.20M | 135.80M | 145.40M | 55.80M | 52.50M | 46.40M | 38.30M | 35.40M | 35.10M | 27.10M | 19.10M | 38.20M | 8.00M | 5.30M | 100.00K |
| Cost & Expenses | 1.17M | 162.43 | 702.80M | 832.00M | 933.70M | 1.27B | 1.08B | 865.10M | 649.30M | 4.80M | 1.63B | 1.31B | 1.49B | 1.19B | 1.17B | 1.10B | 618.20M | 572.70M | 552.40M | 441.50M | 370.00M | 382.20M | 448.50M | 258.10M | 316.30M | 221.40M | 112.00M | 100.00K |
| Interest Income | 3.17M | 9.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | -57.40M | -52.10M | -38.20M | -37.30M | -38.50M | 28.20M | 26.07M | 28.31M | -27.60M | -1.90M | -2.70M | -3.30M | -3.00M | -400.00K | -800.00K | -800.00K | -800.00K | -100.00K | 800.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 23.60M | 27.73M | 21.55M | 22.74M | -81.10M | -16.10M | 73.07M | 15.88M | 12.33M | 5.03M | 6.40M | 7.09M | 10.86M | 9.92M | 5.03M | 5.08M | 6.06M | 6.36M | 4.88M | 3.22M | 1.69M | 1.09M | 780.00K | 370.00K | 90.00K | 0.00 |
| EBITDA | -1.17M | 9.49 | -84.90M | -24.97M | -56.15M | -335.76M | -174.60M | -39.00M | 86.37M | 39.39M | -36.67M | 16.63M | -82.50M | 9.39M | -11.44M | -19.98M | 15.73M | 19.48M | 28.66M | 21.36M | 3.98M | 420.00K | 7.69M | -10.11M | -29.62M | -5.73M | -2.21M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -11.98% | -3.06% | -6.00% | -34.18% | -17.74% | -4.63% | 13.03% | 0.00% | -2.24% | 1.25% | -5.88% | 0.78% | -0.99% | -1.86% | 2.49% | 3.31% | 4.97% | 4.68% | 1.08% | 0.11% | 1.70% | -4.17% | -10.46% | -2.68% | -2.02% | 0.00% |
| Operating Income | -1.17M | -162.43 | -108.50M | -52.70M | -77.70M | -358.50M | -93.50M | -22.90M | 13.30M | 23.51M | -49.00M | 11.60M | -88.90M | 2.30M | -22.30M | -29.90M | 10.70M | 14.40M | 22.60M | 15.00M | -900.00K | -2.80M | 6.00M | -11.20M | -30.40M | -6.10M | -2.30M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -15.31% | -6.45% | -8.30% | -36.50% | -9.50% | -2.72% | 2.01% | 0.00% | -2.99% | 0.87% | -6.34% | 0.19% | -1.93% | -2.79% | 1.70% | 2.45% | 3.92% | 3.29% | -0.24% | -0.74% | 1.33% | -4.62% | -10.73% | -2.85% | -2.10% | 0.00% |
| Total Other Income/Expenses | 3.17M | 9.49 | 57.50M | -14.70M | 45.30M | 33.50M | -38.50M | -28.20M | -26.10M | -28.31M | 27.60M | 1.90M | 2.70M | 3.30M | 3.00M | 300.00K | 800.00K | 800.00K | 800.00K | 100.00K | -800.00K | -1.00M | -1.70M | -2.30M | -1.40M | -700.00K | -200.00K | 0.00 |
| Income Before Tax | 2.00M | -152.95 | -51.00M | -67.40M | -32.40M | -325.00M | -132.00M | -51.10M | -12.80M | -4.80M | -21.40M | 13.50M | -86.20M | 5.60M | -19.30M | -29.60M | 11.50M | 15.20M | 23.40M | 15.10M | -1.70M | -3.80M | 4.30M | -13.50M | -31.80M | -6.80M | -2.50M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -7.19% | -8.25% | -3.46% | -33.09% | -13.41% | -6.07% | -1.93% | 0.00% | -1.31% | 1.02% | -6.15% | 0.47% | -1.67% | -2.76% | 1.82% | 2.58% | 4.06% | 3.31% | -0.46% | -1.01% | 0.95% | -5.57% | -11.23% | -3.18% | -2.29% | 0.00% |
| Income Tax Expense | -3.17M | 9.49 | 600.00K | 63.60M | 2.00M | -21.50M | 11.40M | 2.50M | -4.40M | 28.31M | 47.70M | -40.60M | -12.20M | 2.30M | 19.00M | -5.70M | 4.50M | 6.10M | 4.70M | 900.00K | 100.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Net Income | 5.16M | -152.95 | -51.60M | -131.00M | -34.40M | -303.50M | -143.40M | -53.60M | -8.40M | -33.11M | -69.10M | 54.10M | -74.00M | 3.30M | -38.30M | -23.90M | 7.00M | 9.10M | 18.70M | 14.20M | -1.80M | -4.80M | 2.60M | -15.80M | -33.20M | -7.50M | -2.70M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -7.28% | -16.03% | -3.68% | -30.90% | -14.57% | -6.36% | -1.27% | 0.00% | -4.22% | 4.07% | -5.28% | 0.28% | -3.32% | -2.23% | 1.11% | 1.55% | 3.24% | 3.11% | -0.49% | -1.27% | 0.58% | -6.52% | -11.72% | -3.51% | -2.47% | 0.00% |
| EPS | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| EPS Diluted | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| Weighted Avg Shares Out | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
| Weighted Avg Shares Out (Dil) | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
BioScrip to Present at Jefferies 2011 Global Healthcare Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at the Jefferies 2011 Global Healthcare Conference, to be held June 6-9, 2011, at the Grand Hyatt in New York City. Richard M. Smith, President and Chief Executive...
BioScrip to Present at Upcoming Investor Conferences
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at two investor conferences in May. Thursday, May 12, 2011 at 12:30 pm PST - At the Bank of America 2011 Health Care Conference, to be held May...
BioScrip Reports 2011 First Quarter Financial Results
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced 2011 first quarter financial results. First quarter revenue for the period ended March 31, 2011, was $439.3 million with net income of $2.9 million, or $0.05 per diluted share. Adjusted EBITDA for...
BioScrip to Host First Quarter 2011 Earnings Call
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2011 first quarter financial results before the market opens on Tuesday, May 3, 2011, and host a conference call at 8:30 a.m. Eastern Standard Time (EST) to...
BioScrip Receives URAC Accreditation in Specialty and Mail Service Pharmacy
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) announced today that it has been awarded specialty pharmacy and mail service pharmacy accreditation from URAC, a Washington, D.C.-based health care accrediting organization that establishes quality standards for the health care industry. Specialty pharmacy...
BioScrip Reports 2010 Fourth Quarter and Year-End Financial Results
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) today announced 2010 fourth quarter and year-end financial results. Fourth quarter revenue was $450.4 million with a net loss of $67.1 million, or $1.25 per share, which included a deferred-tax asset valuation allowance expense...
BioScrip to Host Fourth Quarter and Year-End 2010 Earnings Call
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2010 fourth quarter and year-end financial results before the market opens on Friday, March 11, 2011, and host a conference call shortly thereafter at 8:30 a.m. Eastern...
Emerald Holds Annual Groundhog Day Investment Forum
LANCASTER, Pa.--(BUSINESS WIRE)--Emerald Asset Management will hold it’s Eighteenth Annual Emerald Groundhog Day Investment Forum on Wednesday, February 2, 2011 at the Radisson Plaza-Warwick Hotel in Philadelphia. “Energy and passion are hallmarks of the Emerald Groundhog Day Investment Forum,” said...
BioScrip Provides Update on Strategic Assessment to Improve Financial and Operational Performance
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today provided an update of its ongoing strategic assessment and the execution of its plan. The Company is in the process of implementing a two-phased initiative, to include reducing costs and streamlining operations, and to...
MJ Graves Appointed Interim Chief Financial Officer of BioScrip
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that Mary Jane “MJ” Graves, former Chief Financial Officer of Critical Homecare Solutions, Inc. (“CHS”), which was acquired by BioScrip in 2010, has been appointed Interim CFO by the Company’s Board of Directors,...
Source: https://incomestatements.info
Category: Stock Reports